News

Four Skin Cancers Warrant Vigilance as Incidence Rates Rise


 

“This is probably one of the worst cutaneous tumors that we, as dermatologists, can see. It's right up there with a bad angiosarcoma,” he said.

Local recurrences are seen in 25%-33% of cases, regional spread in 25%, and distant metastasis in 33% of cases—50% by some reports—with a 3-year overall survival of 31%.

Treatment is controversial, noted Dr. Brown.

Wide local excision down to the fascia or Mohs surgery with sentinel lymph node biopsy is recommended, guiding the need for total lymph node dissection, postoperative radiation therapy, and perhaps even adjuvant chemotherapy, he said, adding that a negative sentinel lymph node carries a fairly reassuring prognosis.

'It's not at all unusual for me to see patients … in their 40s or 50s with their first lentigo maligna.' DR. BROWN

Pages

Recommended Reading

'Ugly Duckling' Could Be Useful Melanoma Flag
MDedge Family Medicine
Becaplermin Tied to Cancer Death Risk
MDedge Family Medicine
Omalizumab Shows Efficacy for Urticaria
MDedge Family Medicine
COBRA Trial Opens Door to All-Topical Therapy in Psoriasis
MDedge Family Medicine
Dermoscopy May Enhance Melanoma Risk Assessment
MDedge Family Medicine
Value of Melanoma Biopsy Technique Is Revised
MDedge Family Medicine
Watchful Waiting Best in Kids' Neurofibromatosis
MDedge Family Medicine
Eczema Center Emphasizes Research, Education
MDedge Family Medicine
Quality of Sleep Is a Marker of Severity
MDedge Family Medicine
Tanning Industry Launches Attack Against 'Melanoma Hype'
MDedge Family Medicine